デフォルト表紙
市場調査レポート
商品コード
1495421

セラノスティクス市場:製品、用途、エンドユーザー別-2024-2030年の世界予測

Theranostics Market by Product (Product, Services, Software), Application (Bone Metastatis, Cardiovascular Diseases, Lymphoma), End-User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
セラノスティクス市場:製品、用途、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

セラノスティクス市場規模は2023年に23億3,000万米ドルと推計され、2024年には26億7,000万米ドルに達し、CAGR 14.89%で2030年には61億8,000万米ドルに達すると予測されています。

セラノスティクスは、診断学と診断検査結果に基づく標的治療を組み合わせた医学の革新的分野を表しています。このアプローチにより個別化治療が可能になり、個人の疾患特性に合わせた治療を行うことで、より効率的かつ効果的なヘルスケアの提供が可能になります。セラノスティクスの主な用途には、腫瘍学、心血管疾患、神経疾患、感染症などがあります。セラノスティクスのエンドユーザーは、主に病院や診療所、診断研究所、研究機関であり、治療と診断プロセスを統合することで、患者のケアを大幅に向上させることができます。セラノスティクスのニーズが拡大しているのは、世界の対象疾患の有病率の増加です。個別化医療への志向の高まりと分子生物学の進歩が、セラノスティクスの利用を拡大しています。さらに、ヘルスケアインフラの成長と研究開発活動への世界の投資の増加が、セラノスティクス市場成長の主な促進要因となっています。研究開発に関連する高コスト、データのプライバシーや個別化医療の倫理的配慮に関連する問題は、市場成長にとって大きな課題となっています。新規バイオマーカー、非侵襲的イメージング技術、精密治療薬の市場開拓が進むことで、市場成長の機会が生まれると期待されています。データ分析と機械学習の統合は、患者の反応予測モデルの開発、治療レジメンの最適化、疾患進行のモニタリングのフロンティアを提示します。

主な市場の統計
基準年[2023] 23億3,000万米ドル
予測年[2024] 26億7,000万米ドル
予測年 [2030] 61億8,000万米ドル
CAGR(%) 14.89%

地域別インサイト

南北アメリカはセラノスティクス市場開拓のために非常に発展している地域であり、高いヘルスケア支出、堅調な特許登録、個別化医療への多額の投資を特徴としています。個別化医療の利点に対する認識の高まりと、セラノスティクスの研究と応用に対する官民セクターの投資の増加は、南北アメリカにおける市場の基盤を作ると予想されます。欧州連合(EU)では、強力なヘルスケアシステムとともに規制による支援がセラノスティクス市場の成長を促進しています。ドイツ、フランス、英国などの国々が最先端を走っており、がんや神経変性疾患を中心に研究が進められています。中東は、ヘルスケア・インフラへの投資や欧米のバイオテクノロジー企業との提携に後押しされ、新たな関心を示しています。アフリカは、特に医療制度が発展途上にある地域で、利用しやすい診断サービスに重点を置いて潜在力を発揮しています。アジア太平洋地域は、個別化医療における技術革新を後押しする政府のイニシアティブに後押しされ、セラノスティクス分野で重要な地域として急浮上しています。高齢化が進む日本では、特にがんや心血管疾患において、先進的なセラノスティック・ソリューションに対するニーズが高まっています。ヘルスケア分野が成長し、安価な医療を重視するインドでは、地域に根ざしたセラノシス研究や共同研究への投資が増加しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、セラノスティクス市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を調査します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。

市場シェア分析

市場シェア分析は、セラノスティクス市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査対象基準年に観察された蓄積、断片化の優位性、合併特性などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、セラノスティクス市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 対象疾患の蔓延が世界的に増加
      • 個別化医療と分子生物学の進歩
    • 抑制要因
      • 研究開発にかかるコストの高さと規制承認の複雑さ
    • 機会
      • セラノスティクスにおけるデータ分析と機械学習の統合の強化
      • 新しいバイオマーカーと非侵襲的イメージング技術の開発が進む
    • 課題
      • データプライバシーと個別化医療の倫理的配慮
  • 市場セグメンテーション分析
    • 製品:データの取得、処理、分析のためのソフトウェアの使用の増加
    • エンドユーザー:さまざまな疾患の管理における病院におけるセラノスティクスの潜在的可能性の拡大
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 セラノスティクス市場:製品別

  • 製品
  • サービス
  • ソフトウェア

第7章 セラノスティクス市場:用途別

  • 骨転移
  • 心血管疾患
  • リンパ腫
  • 神経内分泌腫瘍
  • 前立腺がん

第8章 セラノスティクス市場:エンドユーザー別

  • がんケアセンター
  • 病院
  • 調査・学術センター
  • セラノスティクスセンター

第9章 南北アメリカのセラノスティクス市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のセラノスティクス市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのセラノスティクス市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • クラリティ社の前立腺がん治療薬臨床試験が最高用量レベルコホートで進展
    • BAMF HealthとGEヘルスケアが協力し、セラノスティクスの成長に向けた持続可能でスケーラブルなソリューションを実現
    • UCLAヘルスがセラノスティクスセンターを開設
  • 戦略分析と提言

第13章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. THERANOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. THERANOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. THERANOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. THERANOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. THERANOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERANOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL THERANOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERANOSTICS MARKET SIZE, BY FUNCTIONAL IMAGING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL THERANOSTICS MARKET SIZE, BY FUNCTIONAL IMAGING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERANOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL THERANOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL THERANOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL THERANOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL THERANOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL THERANOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORINE-18, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL THERANOSTICS MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL THERANOSTICS MARKET SIZE, BY GALLIUM-68, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL THERANOSTICS MARKET SIZE, BY LODINE-131, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL THERANOSTICS MARKET SIZE, BY LODINE-131, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL THERANOSTICS MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL THERANOSTICS MARKET SIZE, BY LUTETIUM-177, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL THERANOSTICS MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL THERANOSTICS MARKET SIZE, BY RADIUM-223, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL THERANOSTICS MARKET SIZE, BY SAMARIUM-153, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL THERANOSTICS MARKET SIZE, BY SAMARIUM-153, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL THERANOSTICS MARKET SIZE, BY STRONTIUM-89, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL THERANOSTICS MARKET SIZE, BY STRONTIUM-89, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNETIUM-99, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNETIUM-99, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL THERANOSTICS MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL THERANOSTICS MARKET SIZE, BY YTTRIUM-90, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL THERANOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL THERANOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL THERANOSTICS MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL THERANOSTICS MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL THERANOSTICS MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL THERANOSTICS MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL THERANOSTICS MARKET SIZE, BY BONE METASTATIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL THERANOSTICS MARKET SIZE, BY BONE METASTATIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL THERANOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL THERANOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL THERANOSTICS MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL THERANOSTICS MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 81. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 82. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 83. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 84. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 85. GLOBAL THERANOSTICS MARKET SIZE, BY THERANOSTICS CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 86. GLOBAL THERANOSTICS MARKET SIZE, BY THERANOSTICS CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 89. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 90. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 91. AMERICAS THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 92. AMERICAS THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 93. AMERICAS THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 94. AMERICAS THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 95. AMERICAS THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 96. AMERICAS THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 97. AMERICAS THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 98. AMERICAS THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 99. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. AMERICAS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. AMERICAS THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 104. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 105. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 106. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 107. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 108. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 109. ARGENTINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 110. ARGENTINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 111. ARGENTINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 112. ARGENTINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 113. ARGENTINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 114. ARGENTINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 115. ARGENTINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 116. ARGENTINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 117. ARGENTINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ARGENTINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ARGENTINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. ARGENTINA THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 122. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 123. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 124. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 125. BRAZIL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 126. BRAZIL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 127. BRAZIL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 128. BRAZIL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 129. BRAZIL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 130. BRAZIL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 131. BRAZIL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 132. BRAZIL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 133. BRAZIL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. BRAZIL THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. BRAZIL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. BRAZIL THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 138. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 139. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 140. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 141. CANADA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 142. CANADA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 143. CANADA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 144. CANADA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 145. CANADA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 146. CANADA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 147. CANADA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 148. CANADA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 149. CANADA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. CANADA THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. CANADA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. CANADA THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 154. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 155. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. MEXICO THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 158. MEXICO THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 159. MEXICO THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 160. MEXICO THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 161. MEXICO THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 162. MEXICO THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 163. MEXICO THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 164. MEXICO THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 165. MEXICO THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. MEXICO THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. MEXICO THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 168. MEXICO THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 169. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 170. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 171. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 172. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 173. UNITED STATES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 174. UNITED STATES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 175. UNITED STATES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 176. UNITED STATES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 177. UNITED STATES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 178. UNITED STATES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 179. UNITED STATES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 180. UNITED STATES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 181. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. UNITED STATES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 184. UNITED STATES THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 185. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 186. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 206. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 208. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 209. AUSTRALIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 210. AUSTRALIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 212. AUSTRALIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 214. AUSTRALIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 216. AUSTRALIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. AUSTRALIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. AUSTRALIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 220. AUSTRALIA THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 221. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 222. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 223. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 224. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 225. CHINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 226. CHINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 227. CHINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 228. CHINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 229. CHINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 230. CHINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 231. CHINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 232. CHINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 233. CHINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. CHINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. CHINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. CHINA THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 238. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 239. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 240. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 241. INDIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 242. INDIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 243. INDIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 244. INDIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 245. INDIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 246. INDIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 247. INDIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 248. INDIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 249. INDIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. INDIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. INDIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. INDIA THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 256. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 257. INDONESIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 258. INDONESIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 259. INDONESIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 260. INDONESIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 261. INDONESIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 262. INDONESIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 263. INDONESIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 264. INDONESIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 265. INDONESIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. INDONESIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. INDONESIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. INDONESIA THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 270. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 271. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 272. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 273. JAPAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 274. JAPAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 275. JAPAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 276. JAPAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 277. JAPAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 278. JAPAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 279. JAPAN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 280. JAPAN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 281. JAPAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. JAPAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. JAPAN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. JAPAN THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 286. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 287. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. MALAYSIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 290. MALAYSIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 291. MALAYSIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 292. MALAYSIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 293. MALAYSIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 294. MALAYSIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 295. MALAYSIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 296. MALAYSIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 297. MALAYSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. MALAYSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. MALAYSIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 300. MALAYSIA THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 301. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 302. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 303. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 304. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 305. PHILIPPINES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 306. PHILIPPINES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 307. PHILIPPINES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 308. PHILIPPINES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 309. PHILIPPINES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 310. PHILIPPINES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 311. PHILIPPINES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 312. PHILIPPINES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 313. PHILIPPINES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 314. PHILIPPINES THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 315. PHILIPPINES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 316. PHILIPPINES THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 317. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 318. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 319. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 320. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 321. SINGAPORE THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 322. SINGAPORE THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 323. SINGAPORE THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 324. SINGAPORE THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 325. SINGAPORE THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 326. SINGAPORE THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 327. SINGAPORE THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 328. SINGAPORE THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 329. SINGAPORE THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 330. SINGAPORE THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 331. SINGAPORE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 332. SINGAPORE THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 333. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 334. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 335. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 336. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 337. SOUTH KOREA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 338. SOUTH KOREA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 339. SOUTH KOREA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 340. SOUTH KOREA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 341. SOUTH KOREA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 342. SOUTH KOREA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 343. SOUTH KOREA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 344. SOUTH KOREA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 345. SOUTH KOREA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 346. SOUTH KOREA THERANOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 347. SOUTH KOREA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 348. SOUTH KOREA THERANOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 349. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 350. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 351. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 352. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 353. TAIWAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2023 (USD MILLION)
  • TABLE 354. TAIWAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2024-2030 (USD MILLION)
  • TABLE 355. TAIWAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2023 (USD MILLION)
  • TABLE 356. TAIWAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2024-2030 (USD MILLION)
  • TABLE 357. TAIWAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 358. TAIWAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 359. TAIWAN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 360. TAIWAN THERANOSTICS MARKET SIZE, BY SOFTWAR
目次
Product Code: MRR-61081604A0A5

[194 Pages Report] The Theranostics Market size was estimated at USD 2.33 billion in 2023 and expected to reach USD 2.67 billion in 2024, at a CAGR 14.89% to reach USD 6.18 billion by 2030.

Theranostics represents an innovative field in medical science that combines diagnostics with targeted therapy based on diagnostic test results. This approach enables personalized treatment, allowing for more efficient and effective healthcare delivery by tailoring treatment to the individual's specific disease characteristics. The primary applications of theranostics include oncology, cardiovascular diseases, neurological disorders, and infectious diseases, among others. The end-users of theranostics are largely hospitals and clinics, diagnostic laboratories, and research institutions, where the integration of therapeutic and diagnostic processes can significantly enhance patient care. The increasing prevalence of target diseases worldwide is expanding the need for theranostics. The growing inclination towards personalized medicines and rising advancements in molecular biology are expanding the usage of theranostics. Additionally, the growth of healthcare infrastructure and increasing investments in R&D activities globally serve as key drivers for the growth of the theranostics market. High costs associated with R&D and issues related to data privacy and the ethical considerations of personalized medicine pose significant challenges to market growth. Growing development of novel biomarkers, non-invasive imaging techniques, and precision therapeutics are expected to create opportunities for market growth. The integration of data analytics and machine learning presents a frontier for developing predictive models for patient response, optimizing treatment regimens, and monitoring disease progression.

KEY MARKET STATISTICS
Base Year [2023] USD 2.33 billion
Estimated Year [2024] USD 2.67 billion
Forecast Year [2030] USD 6.18 billion
CAGR (%) 14.89%

Regional Insights

The Americas represents a highly developing landscape for theranostics market development, characterized by high healthcare expenditure, robust patent registrations, and significant investments in personalized medicine. Growing awareness of personalized healthcare benefits with rising public and private sector investments for research and application in theranostics are expected to create a platform for the market in the Americas. In the European Union (EU), regulatory support, along with strong healthcare systems, promotes the growth of the theranostics market. Countries including Germany, France, and the UK are at the forefront, with research centered on oncology and neurodegenerative diseases. The Middle East shows emerging interest, propelled by investments in healthcare infrastructure and partnerships with Western biotech firms. Africa displays potential particularly in regions with developing healthcare systems, focusing on accessible diagnostic services. Asia Pacific is rapidly emerging as a significant region in the theranostics field, backed by government initiatives aimed at boosting innovation in personalized medicine. Japan's aging population drives need for advanced theranostic solutions, particularly in oncology and cardiovascular diseases. India, with its growing healthcare sector and focus on affordable care, is witnessing increased investment in localized theranostic research and collaborations.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Theranostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing prevalence of target diseases globally
      • Rising advancements in personalized medicine and molecular biology
    • Market Restraints
      • High costs associated with R&D and the complexity of regulatory approvals
    • Market Opportunities
      • Increasing integration of data analytics and machine learning in theranostics
      • Growing development of novel biomarkers and non-invasive imaging techniques
    • Market Challenges
      • Data privacy and the ethical considerations of personalized medicine
  • Market Segmentation Analysis
    • Product: Rising usage of software for data acquisition, processing, and analysis
    • End-User: Growing potential of theranostics among hospitals for the management of a variety of diseases
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Theranostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Theranostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort

Clarity Pharmaceuticals announced the positive progression of its phase I/IIa SECuRE trial, evaluating the novel theranostic agent 64Cu/67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer (mCRPC) patients. In the latest update, the trial's cohort 3, operating under a 3+3 study design, treated three participants with the highest dose of 12GBq of 67Cu-SAR-bisPSMA, demonstrating promising safety and efficacy outcomes. This advancement, along with continued positive outcomes, particularly under the FDA's Expanded Access Program (EAP), underscores SAR-bisPSMA's promise to improve treatment outcomes for prostate cancer patients. [Published On: 2023-11-29]

BAMF Health and GE HealthCare Collaborate to Enable Sustainable and Scalable Solutions for Growth in Theranostics

GE Healthcare and BAMF Health have collaborated to accelerate the adoption of theranostic solutions across the U.S., emphasizing the importance of innovative technologies and services to enhance patient care. By integrating GE HealthCare's comprehensive solutions and BAMF Health's expertise in molecular imaging and theranostics, this partnership is poised to establish a robust framework for the deployment of precision medicine. [Published On: 2023-11-13]

UCLA Health to Open Theranostics Center

UCLA Health is gearing up to launch its pioneering outpatient theranostics center later this year, marking a significant milestone in the treatment of advanced cancer. This state-of-the-art 3,000-square-foot facility situated on the Westwood campus's 100 Medical Plaza building is designed to optimize patient care. With eight infusion chairs, the center aims to deliver up to 80 transfusions weekly, amounting to 4,000 treatment cycles annually, primarily focusing on patients with advanced prostate cancer, neuroendocrine tumors, and thyroid cancer. [Published On: 2023-05-22]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Theranostics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Theranostics Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Ariceum Therapeutics GmbH, Astellas Pharma Inc., BAMF Health, Bayer AG, bioMerieux SA, Biosynth Ltd., Cardinal Health, Inc., Cerebral Therapeutics, Inc., Clarity Pharmaceuticals, Curasight A/S, Curium Inc., Evergreen Theragnostics, Inc., GE HealthCare Technologies, Inc., Hermes Medical Solutions AB, Icon Group, Indi Molecular, Inc., Integrated Clinical Oncology Network Pty Ltd., Invicro, LLC, Ipsen Pharma, Radiopharm Theranostics Limited, Ratio Therapeutics, Siemens Healthineers AG, SOFIE Co., Telix Pharmaceuticals Limited, and United Theranostics.

Market Segmentation & Coverage

This research report categorizes the Theranostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Product
      • Diagnostic Imaging
        • Functional Imaging
        • Molecular Imaging
        • Nuclear Imaging
      • In Vitro Diagnostics/Biomarker Screening
        • Fluorescence In Situ Hybridization
        • Next-generation Sequencing
        • Polymerase Chain Reaction
      • Radiopharmaceuticals
        • Fluorine-18
        • Gallium-68
        • lodine-131
        • Lutetium-177
        • Radium-223
        • Samarium-153
        • Strontium-89
        • Technetium-99
        • Yttrium-90
    • Services
    • Software
      • Imaging Analytics
      • Predictive Modeling
  • Application
    • Bone Metastatis
    • Cardiovascular Diseases
    • Lymphoma
    • Neuroendocrine Tumors
    • Prostate Cancer
  • End-User
    • Cancer Care Centers
    • Hospitals
    • Research & Academic Centers
    • Theranostics Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of target diseases globally
      • 5.1.1.2. Rising advancements in personalized medicine and molecular biology
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D and the complexity of regulatory approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing integration of data analytics and machine learning in theranostics
      • 5.1.3.2. Growing development of novel biomarkers and non-invasive imaging techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Data privacy and the ethical considerations of personalized medicine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising usage of software for data acquisition, processing, and analysis
    • 5.2.2. End-User: Growing potential of theranostics among hospitals for the management of a variety of diseases
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Theranostics Market, by Product

  • 6.1. Introduction
  • 6.2. Product
  • 6.3. Services
  • 6.4. Software

7. Theranostics Market, by Application

  • 7.1. Introduction
  • 7.2. Bone Metastatis
  • 7.3. Cardiovascular Diseases
  • 7.4. Lymphoma
  • 7.5. Neuroendocrine Tumors
  • 7.6. Prostate Cancer

8. Theranostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Care Centers
  • 8.3. Hospitals
  • 8.4. Research & Academic Centers
  • 8.5. Theranostics Centers

9. Americas Theranostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Theranostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Theranostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort
    • 12.3.2. BAMF Health and GE HealthCare Collaborate to Enable Sustainable and Scalable Solutions for Growth in Theranostics
    • 12.3.3. UCLA Health to Open Theranostics Center
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio